Q2 2026 delivered record sales in the Americas and strong reagent growth in APAC, offsetting challenges in China and EMEA inventory adjustments. EBITDA margin was 27%, impacted by CEO transition costs, while innovation and new product launches support a positive outlook.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.